2. Search Result
Search Result
Results for "

SOS1+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145926
    MRTX0902
    2 Publications Verification

    		 SOS1 Ras Neurological Disease Cancer
    MRTX0902 is a potent, selective, brain-penetrant, and orally active SOS1 inhibitor with a Ki of 1.9 nM. MRTX0902 disrupts the SOS1:KRASG12C protein-protein interaction (PPI). MRTX0902 can be used in research on pancreatic ductal adenocarcinoma [1].
    MRTX0902
  • HY-151881
    SOS1-IN-15

    		SOS1 Ras Cancer
    SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM. SOS1-IN-15 is a promising agent candidate for the research of KRAS-driven cancer [1].
    SOS1-IN-15
  • HY-134885
    RMC-0331
    1 Publications Verification

    RM-023

    		 SHP2 SOS1 Ras Cancer
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction [1].
    RMC-0331
  • HY-163939
    RGT-018

    		SOS1 Ras Cancer
    RGT-018 is a potent and orally active SOS1 inhibitor with anti-tumor effects. RGT-018 exerts anti-cancer cell proliferation activity by inhibiting KRAS activation [1].
    RGT-018
  • HY-148261
    KRAS G12C inhibitor 56

    		Ras Cancer
    KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC50 of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research [1].
    KRAS G12C inhibitor 56
  • HY-179443
    SOS1-IN-25

    		SOS1 Ras Cancer
    SOS1-IN-25 is an SOS1 inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRAS G12C/SOS1 complex formation (IC50 = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia [1].
    SOS1-IN-25
  • HY-151517
    SOS1-IN-14

    		SOS1 Ras Cancer
    SOS1-IN-14 is a potent, selective and orally active SOS1 inhibitor with an IC50 value of 3.9 nM. SOS1-IN-14 can be absorbed in the intestine via a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 can be used to research KRAS-mutated cancers. SOS1-IN-14 has better potent tumor suppression than BI-3406 (HY-125817) [1].
    SOS1-IN-14
  • HY-175560
    SOS1-IN-22

    		SOS1 PERK Cancer
    SOS1-IN-22 is a son of sevenless homolog 1 (SOS1) inhibitor. SOS1-IN-22 can inhibit KRAS-G12C/SOS1 complex formation with an IC50 value of 40.28 nM. SOS1-IN-22 can reduce phosphorylation ERK levels. SOS1-IN-22 can be used for the research of cancer, such as pancreatic carcinoma and appendiceal carcinoma [1].
    SOS1-IN-22
  • HY-144212
    SOS1-IN-8

    		SOS1 Ras Cancer
    SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2) [1].
    SOS1-IN-8
  • HY-144210
    SOS1-IN-6

    		SOS1 Ras Cancer
    SOS1-IN-6 (compound 33-P1) is a potent SOS1 inhibitor with IC50s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively [1].
    SOS1-IN-6
  • HY-178044
    SOS1-IN-24

    		SOS1 Cancer
    SOS1-IN-24 (Compound 15) is a SOS1 inhibitor with an IC50 of 0.398  μM. SOS1-IN-24 effectively disrupts SOS1::KRAS12D interaction. SOS1-IN-24 can be used for cancers like pancreatic and colorectal cancer research [1].
    SOS1-IN-24
  • HY-175244
    SOS1-IN-20

    		SOS1 Ras Potassium Channel Cancer
    SOS1-IN-20 (Compound 12f) is an orally active SOS1 inhibitor with an IC50 of 5.11 nM against KRAS G12C::SOS1. By disrupting the interaction between KRAS and SOS1, SOS1-IN-20 inhibits KRAS activation and downstream signal transduction. SOS1-IN-20 has an IC50 of 253 nM for p-ERK in PC-9 cells and 16.71 μM for hERG channel . SOS1-IN-20 can inhibit the proliferation of tumor cells and has antitumor activity [1].
    SOS1-IN-20
  • HY-144962
    SOS1-IN-11

    		SOS1 Ras Cancer
    SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM.
    SOS1-IN-11
  • HY-161714
    HH0043

    		SOS1 Ras Cancer
    HH0043 (Compound 10f) is an orally active and potent SOS1 inhibitor, with IC50 value of 5.8 nM. HH0043 can be used for the research of cancer [1].
    HH0043
  • HY-144213
    SOS1-IN-10

    		SOS1 Ras Cancer
    SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8) [1].
    SOS1-IN-10
  • HY-144207
    SOS1-IN-9

    		SOS1 Ras Cancer
    SOS1-IN-9 is a potent SOS1 inhibitor with an IC50 of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302) [1].
    SOS1-IN-9
  • HY-101796
    NSC-70220

    		Ras SOS1 Cancer
    NSC-70220 is a selective and allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation, and partially inhibited catalytic site activation. NSC-70220 has an anticancer effect [1].
    NSC-70220
  • HY-145047
    SOS1-IN-4

    		SOS1 Ras Cancer
    SOS1-IN-4 is a potent SOS1 inhibitor with an IC50 of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65) [1].
    SOS1-IN-4
  • HY-144965
    SOS1-IN-12

    		SOS1 Ras Cancer
    SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer [1].
    SOS1-IN-12
  • HY-144967
    SOS1-IN-13

    		SOS1 Ras Cancer
    SOS1-IN-13 is a potent son of sevenless homolog 1 (SOS1) inhibitor with IC50s of 6.5 nM and 327 nM for SOS1 and pERK, respectively. SOS1-IN-13 can be used for researching anticancer [1].
    SOS1-IN-13
  • HY-144211
    SOS1-IN-7

    		SOS1 Ras Cancer
    SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively [1].
    SOS1-IN-7
  • HY-101796R
    NSC-70220 (Standard)

    		Ras SOS1 Reference Standards Cancer
    NSC-70220 (Standard) is the analytical standard of NSC-70220 (HY-101796). This product is intended for research and analytical applications. NSC-70220 is a selective and allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation, and partially inhibited catalytic site activation. NSC-70220 has an anticancer effect [1].
    NSC-70220 (Standard)
  • HY-183365
    SL43

    		SOS1 Ras p38 MAPK ERK MEK Apoptosis Cancer
    SL43 is an orally active and potent SOS1 inhibitor with a Kd of 0.16 μM. SL43 disrupts SOS1-KRAS interaction, inhibits SOS1-mediated nucleotide exchange on KRAS mutants, and suppresses RAS-MAPK signaling. SL43 exerts antiproliferative activity against KRAS-mutant cancer cells, induces early apoptosis and G1 phase cell cycle arrest, and reduces phosphorylated MEK and ERK levels. SL43 suppresses tumor growth in a colorectal cancer xenograft model [1].
    SL43

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: